Q-omics provides the consensus-scored PABPC1P10 profile across patient tissues and cancer cell-line models. PABPC1P10 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PABPC1P10 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PABPC1P10 RNA expression shows 13,616 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, COAD, and UVM as cancer lineages where PABPC1P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PABPC1P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PABPC1P10 survival associations across molecular data types. PABPC1P10 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PABPC1P10 RNA expression–survival associations across cancer types. High PABPC1P10 expression shows unfavorable associations in KICH, UVM, OV, DLBC and LUSC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PABPC1P10 RNA expression.
This table summarizes PABPC1P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PABPC1P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PABPC1P10 shows lower tumor expression in THCA and higher tumor expression in COAD, LUAD, KIRC, LUSC and HNSC. The COAD box plot shows higher PABPC1P10 RNA expression in tumor versus normal tissue (log2 FC = +0.935, t-test p < 0.001).
This table shows molecular features associated with PABPC1P10 in patient tissues and cancer cell lines. In patient samples, PABPC1P10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
